Lineage Cell Therapeutics
LCTX
LCTX
58 hedge funds and large institutions have $60.8M invested in Lineage Cell Therapeutics in 2013 Q4 according to their latest regulatory filings, with 10 funds opening new positions, 17 increasing their positions, 11 reducing their positions, and 8 closing their positions.
New
Increased
Maintained
Reduced
Closed
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more first-time investments, than exits
New positions opened: | Existing positions closed:
more funds holding
Funds holding: →
more funds holding in top 10
Funds holding in top 10: →
5% less capital invested
Capital invested by funds: $63.8M → $60.8M (-$3.03M)
4.79% less ownership
Funds ownership: 35.98% → 31.19% (-4.8%)
92% less call options, than puts
Call options by funds: $32K | Put options by funds: $407K
Holders
58
Holding in Top 10
1
Calls
$32K
Puts
$407K
Top Buyers
| 1 | +$1.08M | |
| 2 | +$741K | |
| 3 | +$444K | |
| 4 |
D.E. Shaw & Co
New York
|
+$280K |
| 5 |
VKH
Virtu KCG Holdings
New York
|
+$255K |
Top Sellers
| 1 | -$3.02M | |
| 2 | -$320K | |
| 3 | -$160K | |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$137K |
| 5 |
ProShare Advisors
Bethesda,
Maryland
|
-$89K |